NCT01263509 - Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan | Biotech Hunter

Enrollment

179

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Alogliptin and voglibose

Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.

DRUG

Alogliptin and voglibose

Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.